Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Bionano Genomics, Inc.
BNGO
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $13.4M
$1.15
▼ -1.71%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$1.06 - $5.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 65.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Optical Genome Mapping Technology - Superior to traditional sequencing for structural variation detection
- Comprehensive Clinical Testing Portfolio - Integrated diagnostics covering developmental, neurological, and psychiatric conditions
- Established Laboratory Infrastructure - CLIA-certified testing services with growing patient base
- Differentiated Market Position - Less competitive landscape compared to traditional NGS providers
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Strong growth ahead
Increasing adoption of structural variant analysis in clinical diagnostics and research
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Stable
-2.5% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BNGO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 13, 2026
MAY 13, 2026
Reported EPS of -$0.76 vs -$0.88 consensus (+13.6% surprise). Revenue of $6.7M vs $6.6M expected (+1.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+13.6%
Next: Aug 13, 2026
Revenue trend · last 8Q
—
—
—
-26%
-13%
+21%
-3%
-100%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$7.8M
$6.1M
$8.2M
$6.5M
$6.7M
$7.4M
$8.0M
$6.7K
Margins · last 8Q
Gross
—
Operating
—
Profit
-124.2%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Apr 13, 2026